title: Structural mechanism for heparin-binding of the third Kunitz domain of human tissue factor pathway inhibitor.
abstract: Tissue factor pathway inhibitor (TFPI) inhibits the activity of coagulation factor VIIa and Xa through its K1 and K2 domain, respectively, and the inhibitory activity is enhanced by heparin. The function of the K3 domain of TFPI has not been established, but the domain probably harbors a heparin binding site (HBS-2). We determined the three-dimensional solution structure of the TFPI K3 domain (Glu182-Gly242) by heteronuclear multidimensional NMR. The results showed that the molecule is composed of one antiparallel beta-sheet and one alpha-helix, and in overall structure is very similar to the K2 domain, with the rms deviation of 1.55 A for the 58 defined C(alpha) positions. However, the surface electrostatic properties of both domains are different each other. The lack of inhibitory activity of the K3 domain is explained by the absence of electrostatic interaction with factor Xa over a large surface area. A titration experiment with size-fractionated heparin showed that a heparin binding site was located in the vicinity of the alpha-helix. In this region, a positively charged cluster is formed by Lys213, Lys232, and Lys240, and the negatively charged sulfate groups of heparin bind there. The enhancement of inhibitory activity by heparin probably was not due to a conformational change to TFPI itself. It is likely that heparin simply increases the local concentration of TFPI on the cell surface and stabilizes the initial complex that forms.
authors.affiliation: National Cardiovascular Center Research Institute, 5 Fujishirodai, Suita, Osaka 565-8565 Japan.
authors.forename: Shouhei
authors.initials: S
authors.lastname: Mine
authors.forename: Toshio
authors.initials: T
authors.lastname: Yamazaki
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Miyata
authors.forename: Saburo
authors.initials: S
authors.lastname: Hara
authors.forename: Hisao
authors.initials: H
authors.lastname: Kato
mesh_terms: D000595:Amino Acid Sequence; D000925:Anticoagulants / Q000378:metabolism*; D007611:Aprotinin / Q000737:chemistry / Q000302:isolation & purification / Q000378:metabolism; D001665:Binding Sites; D017931:DNA Primers / Q000737:chemistry; D065427:Factor Xa Inhibitors; D006493:Heparin / Q000378:metabolism*; D006801:Humans; D008074:Lipoproteins / Q000737:chemistry* / Q000378:metabolism*; D008958:Models, Molecular; D008969:Molecular Sequence Data; D019906:Nuclear Magnetic Resonance, Biomolecular; D009844:Oligosaccharides / Q000737:chemistry; D016133:Polymerase Chain Reaction; D011485:Protein Binding; D011487:Protein Conformation; D011994:Recombinant Proteins / Q000737:chemistry / Q000302:isolation & purification / Q000378:metabolism; D015842:Serine Proteinase Inhibitors / Q000737:chemistry / Q000378:metabolism
chemical_list: D000925:Anticoagulants; D017931:DNA Primers; D065427:Factor Xa Inhibitors; D008074:Lipoproteins; D009844:Oligosaccharides; D011994:Recombinant Proteins; D015842:Serine Proteinase Inhibitors; C051928:lipoprotein-associated coagulation inhibitor; C098973:recombinant Kunitz protease inhibitor; D006493:Heparin; D007611:Aprotinin